Target

ERK

Aliases

7 products, 5 indications

Indications

ER+HER2- breast cancer (4 products)

KRAS G12C-mutated solid tumors (1 products)

RAS or RAF mutated solid tumors (1 products)

glioblastoma (1 products)

Metastatic Castration-Resistant Prostate Cancer (1 products)

5 drugs

4 abstracts

Abstract

Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Investigational Cancer Therapeutics,

Abstract

Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study.

Org: Johns Hopkins University Hospital,

Abstract

Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).

Org: University of Texas MD Anderson Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,

Abstract

PUF: A potential repressor of oncogenes.

Org: East Carolina University Brody School of Medicine, East Carolina University/Vidant Cancer Center,

Drug

Drug

Drug

Drug

Drug